One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Plasma Fractionation Market

[ 英語タイトル ] Plasma Fractionation Market by Product (IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor), Application (Immunology, Hematology, Critical Care, Rheumatology), End User (Hospital, Clinic, Academic Institute) - Global Forecast to 2023


Product Code : MNMHC00109330
Survey : MarketsandMarkets
Publish On : February, 2021
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD5650 / Question Form
5 User USD6650 / Question Form
Enterprise User USD10000 / Question Form

[Report Description]

The plasma fractionation market is projected to reach to USD 29.50 billion by 2023 from an estimated USD 21.23 billion in 2018. The growing geriatric population across the globe, increasing use of immunoglobulins in various therapeutic areas, growing prevalence of respiratory diseases and uptake of alpha-1-antitrypsin, and increase in plasma collection are the factors driving this market. However, the emergence of recombinant alternatives, high cost of plasma products, and limited reimbursement may hinder the growth of this market.

The protease inhibitors segment is expected to grow at the highest CAGR during the forecast period
On the basis of product, the plasma fractionation market is segmented into immunoglobulins, coagulation factor concentrates, albumin, protease inhibitors, and other plasma products. The protease inhibitors segment is expected to witness the highest growth during the forecast period. The high growth of this segment is primarily attributed to the increasing prevalence of alpha-1 antitrypsin deficiency and increasing number of various respiratory diseases.

The pulmonology segment is projected to witness the highest growth during the forecast period
Based on the application, the plasma fractionation market is classified into neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications. The pulmonology segment
is expected to grow at the highest CAGR during the forecast period. This can largely be attributed to the increasing use of immunoglobulins and protease inhibitors in the treatment of various respiratory diseases such as AATD and COPD, asthma, and respiratory tract infections.

The hospitals and clinics segment is expected to grow at the highest CAGR during the forecast period
On the basis of type of end user, the market is segmented into hospitals & clinics, clinical research laboratories, and academic institutes. During the forecast period, the hospitals & clinics segment is expected to grow at the highest CAGR. The high growth of this segment can be attributed to the increasing adoption of plasma products in the treatment of various immunological, neurological, and bleeding disorders; large patient pool treated in hospitals; growing number of hospitals & clinics across the globe; and increasing number of collaborations between the manufacturers of plasma products and hospitals.

Asia Pacific to witness the highest growth during the forecast period
Asia Pacific is expected to witness the highest growth during the forecast period (2018 to 2023). The region’s large geriatric population, large population, improving healthcare infrastructure, increasing incidences of immunological and bleeding diseases, increasing focus diagnosis and prophylactic treatment, and increasing awareness about technologically advanced products are driving the growth of this market.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–46%, Tier 2–33% and Tier 3–21%
• By Designation – C Level–43%, Director Level–35%, Others–22%
• By Region – North America–34%, Europe–26%, Asia Pacific–24%, Latin America–12%, Middle East and Africa- 4%
Some of the major market players in the plasma fractionation market are CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), Bio Product Laboratory (UK), Sanquin (Netherlands), LFB (France), Biotest (Germany), Japan Blood Products Organization, China Biologic Products (China), Green Cross Corporation (South Korea), and Shanghai RAAS Blood Products (China).
Research Coverage:
The report analyzes the plasma fractionation market and aims at estimating the market size and future growth potential of this market based on various segments such as product, application, end user, and region. The report also includes a volume data analysis for various plasma products across the globe and a competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global plasma fractionation market. The report analyzes the global plasma fractionation market by product, application, end user, and region.
• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global plasma fractionation market.
• Market Development: Comprehensive information on the lucrative emerging markets by product, application, end user, and region.
• Market Diversification: Exhaustive information about new products, growing geographies, recent developments, and investments in the global plasma fractionation market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of leading players in the global plasma fractionation market.

TABLE OF CONTENTS

1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.3 SCOPE OF THE STUDY 20
1.3.1 MARKETS COVERED 20
1.3.2 YEARS CONSIDERED FOR THE STUDY 21
1.4 CURRENCY 21
1.5 STAKEHOLDERS 21
2 RESEARCH METHODOLOGY 22
2.1 RESEARCH APPROACH 22
2.1.1 SECONDARY SOURCES 23
2.1.1.1 Key data from secondary sources 23
2.1.2 PRIMARY SOURCES 24
2.1.2.1 Key data from primary sources 24
2.1.2.2 Key industry insights 25
2.2 MARKET SIZE ESTIMATION 26
2.2.1 BOTTOM-UP APPROACH 26
2.2.2 TOP-DOWN APPROACH 27
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 28
2.4 MARKET SHARE ESTIMATION 29
2.5 ASSUMPTIONS FOR THE STUDY 29
2.6 LIMITATIONS 29
3 EXECUTIVE SUMMARY 30
4 PREMIUM INSIGHTS 34
4.1 PLASMA FRACTIONATION MARKET OVERVIEW 34
4.2 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018 35
4.3 GEOGRAPHICAL SNAPSHOT OF THE PLASMA FRACTIONATION MARKET 36
4.4 PLASMA FRACTIONATION MARKET: REGIONAL MIX 37
4.5 PLASMA FRACTIONATION MARKET, DEVELOPING COUNTRIES VS.
DEVELOPED COUNTRIES 37

5 MARKET OVERVIEW 38
5.1 INTRODUCTION 38
5.2 MARKET DYNAMICS 38
5.2.1 MARKET DRIVERS 39
5.2.1.1 Growing use of immunoglobulins in various therapeutic areas 39
5.2.1.2 Rising geriatric population across the globe 40
5.2.1.3 Growing prevalence of respiratory diseases and AATD driving the uptake of alpha-1-antitrypsin 41
5.2.1.4 Increase in plasma collection 42
5.2.2 MARKET RESTRAINTS 44
5.2.2.1 High cost and limited reimbursement 44
5.2.2.2 Emergence of recombinant alternatives 44
5.2.3 MARKET OPPORTUNITY 45
5.2.3.1 Increasing number of hemophilia patients 45
5.2.4 MARKET CHALLENGE 46
5.2.4.1 Stringent government regulations 46
6 INDUSTRY INSIGHTS 48
6.1 INTRODUCTION 48
6.2 KEY INDUSTRY TRENDS 49
6.2.1 FOCUS ON INCREASING FRACTIONATION CAPACITIES AND GEOGRAPHICAL EXPANSIONS 50
6.2.2 NEW INDICATIONS FOR PLASMA PRODUCTS 51
6.2.3 RISING ADOPTION OF SCIG 51
6.2.4 INCREASING NUMBER OF FRACTIONATOR-OWNED PLASMA COLLECTION CENTERS 52
6.2.5 GROWING PLASMA PRODUCTS MARKET IN CHINA 53
6.2.6 INCREASING FOCUS OF PLASMA FRACTIONATORS TOWARDS MANUFACTURING AND DEVELOPING RECOMBINANT FACTORS 55
6.3 PORTER’S FIVE FORCES 57
6.3.1 THREAT FROM NEW ENTRANTS 57
6.3.2 THREAT OF SUBSTITUTES 58
6.3.3 BARGAINING POWER OF SUPPLIERS 58
6.3.4 BARGAINING POWER OF BUYERS 59
6.3.5 INTENSITY OF COMPETITIVE RIVALRY 59
6.4 VENDOR BENCHMARKING 60

7 PLASMA FRACTIONATION MARKET, BY PRODUCT 62
7.1 INTRODUCTION 63
7.2 IMMUNOGLOBULIN 64
7.2.1 INTRAVENOUS IMMUNOGLOBULIN (IVIG) 66
7.2.2 SUBCUTANEOUS IMMUNOGLOBULIN (SCIG) 70
7.2.3 OTHER IMMUNOGLOBULINS 72
7.3 COAGULATION FACTOR CONCENTRATES 75
7.3.1 FACTOR VIII 77
7.3.2 FACTOR IX 80
7.3.3 VON WILLEBRAND FACTOR 83
7.3.4 PROTHROMBIN COMPLEX CONCENTRATE 84
7.3.5 FIBRINOGEN CONCENTRATES 86
7.3.6 FACTOR XIII 87
7.4 ALBUMIN 89
7.5 PROTEASE INHIBITORS 92
7.6 OTHER PLASMA PRODUCTS 94
8 PLASMA FRACTIONATION MARKET, BY APPLICATION 95
8.1 INTRODUCTION 96
8.2 NEUROLOGY 97
8.3 IMMUNOLOGY 99
8.4 HEMATOLOGY 101
8.5 CRITICAL CARE 104
8.6 PULMONOLOGY 105
8.7 HEMATO-ONCOLOGY 107
8.8 RHEUMATOLOGY 108
8.9 OTHER APPLICATIONS 110
9 PLASMA FRACTIONATION MARKET, BY END USER 112
9.1 INTRODUCTION 113
9.2 HOSPITALS & CLINICS 114
9.3 CLINICAL RESEARCH LABORATORIES 115
9.4 ACADEMIC INSTITUTES 117
10 GEOGRAPHIC ANALYSIS 119
10.1 INTRODUCTION 120
10.2 NORTH AMERICA 122
10.2.1 US 127
10.2.2 CANADA 132

10.3 EUROPE 135
10.3.1 GERMANY 141
10.3.2 FRANCE 145
10.3.3 ITALY 148
10.3.4 SPAIN 152
10.3.5 UK 155
10.3.6 REST OF EUROPE 159
10.4 ASIA PACIFIC 163
10.4.1 CHINA 167
10.4.2 JAPAN 170
10.4.3 INDIA 174
10.4.4 MALAYSIA 177
10.4.5 REST OF ASIA PACIFIC 181
10.5 LATIN AMERICA 184
10.6 MIDDLE EAST & AFRICA 187
11 COMPETITIVE LANDSCAPE 191
11.1 OVERVIEW 191
11.2 MARKET SHARE ANALYSIS 192
11.3 COMPETITIVE SCENARIO AND TRENDS 194
11.3.1 EXPANSIONS 194
11.3.2 PRODUCT LAUNCHES 195
11.3.3 ACQUISITIONS 195
11.3.4 AGREEMENTS, COLLABORATIONS, JOINT VENTURES, AND PARTNERSHIPS 196
12 COMPANY PROFILES 197
(Overview, Strength of Product Portfolio, Business Strategy Excellence, Products Offering, and Recent Developments)*
12.1 CSL 197
12.2 GRIFOLS 201
12.3 SHIRE 205
12.4 OCTAPHARMA 209
12.5 KEDRION 211
12.6 LFB 215
12.7 BIOTEST 218
12.8 SANQUIN 221
12.9 CHINA BIOLOGIC PRODUCTS 223
12.10 BIO PRODUCTS LABORATORY (BPL) 226

12.11 JAPAN BLOOD PRODUCTS ORGANIZATION 228
12.12 GREEN CROSS CORPORATION 231
12.13 SHANGHAI RAAS BLOOD PRODUCTS 234
*Details on Overview, Strength of Product Portfolio, Business Strategy Excellence, Products Offering, and Recent Developments might not be captured in case of unlisted companies.
13 APPENDIX 236
13.1 INSIGHTS OF INDUSTRY EXPERTS 236
13.2 DISCUSSION GUIDE 237
13.3 AVAILABLE CUSTOMIZATION 241
13.4 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 242
13.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 244
13.6 RELATED REPORT 246
13.7 AUTHOR DETAILS 247

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+